Authors
Yuyu Wei, Yuanfeng Du, Jie Zhang, Wenhao Zheng, Haiyang Wang, Ding Wang, Wenhua Yu, Quan Du, Yang Cao
Published in
Cytotechnology. Volume 78. Issue 6. Pages 218. Epub Oct 23, 2026.
Abstract
Neuroinflammation represents a key pathological process in early brain injury (EBI) following subarachnoid hemorrhage (SAH) and contributes significantly to poor outcomes. Silymarin, known for its anti-inflammatory and antioxidant activities, has been shown to exert neuroprotective effects. Nevertheless, the molecular mechanisms underlying these effects remain to be clarified. An in vivo endovascular perforation model and an in vitro hemoglobin-stimulated model were used to investigate the pharmacological effects of silymarin in SAH. Neurological function was assessed using SAH scores and neurobehavioral scores. Neuronal apoptosis was evaluated by TUNEL staining. Neuroinflammation was measured by ELISA or qPCR, and microglial polarization status was determined by assessing CD86 and CD206 expression via Western blotting (WB) or immunofluorescence (IF) staining. Ruxolitinib and AS1517499 were applied to block the JAK1/STAT6 pathway. Silymarin attenuated early brain injury (EBI) after SAH, as indicated by improved neurological scores, reduced neuronal apoptosis, and lower brain water content. In vivo, silymarin treatment was associated with JAK1/STAT6 activation, elevated M2 markers, and decreased pro‑inflammatory cytokines. In vitro, silymarin activated the JAK1/STAT6 pathway, promoted M2 microglial polarization, and suppressed inflammatory cytokine production. In addition, pharmacological blockade of JAK1/STAT6 reversed silymarin's protective effects, confirming a causal role of this pathway in the cellular context. Our in vitro data demonstrate that silymarin directly stimulates JAK1/STAT6 to drive M2 polarization and anti‑inflammatory responses. In vivo, we observed a correlation between pathway activation and neuroprotective benefits. Together, these findings provide a rationale for further exploring silymarin‑based therapies in SAH.
The online version contains supplementary material available at https://doi.org/10.1007/s10616-026-01073-w.
PMID:
42927074
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 20
- Comments 0